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Objective: To assess changes in health-related quality of life (HRQOL) and to determine whether co-occurring substance use and
medical comorbidities were associated with worse HRQOL over a 1-year period in a naturalistic sample of patients with bipolar
disorder. Method: Patients enrolled in the Continuous Improvement for Veterans in Care: Mood Disorders (CIVIC-MD), a large
prospective study from July 2004 to July 2006, completed baseline and follow-up assessments related to bipolar symptoms,
comorbidity, and Short Form 12 HRQOL assessment at baseline and at 1 year later. Predictors of changes in HRQOL mental and
physical health component scores were determined, using multivariable linear regression models and path analyses. Results: Of 334
participants, the mean age was 49 years (standard deviation [SD]  10.1 years; range  21–78 years), 15.9% women, and 10.8%
African American. At baseline, 19.8% reported hazardous drinking, 25.5% reported illicit drug use, and the mean number of
co-occurring medical conditions was 2.70 (SD  2.02). Illicit drug use was associated with worse mental HRQOL (  2.01;
p  .05), and increased number of medical comorbidities was significantly associated with worse physical HRQOL over time ( 
0.71; p  .01). Depressive symptoms exhibited a strong and consistent influence on mental health scores over time, but path
analyses revealed that they did not seem to mediate effects of comorbidities on lower HRQOL. Conclusions: Illicit drug use and
medical comorbidity negatively affected mental HRQOL over time, independent of bipolar symptoms, suggesting the need for
interventions that address physical health and drug treatment needs for patients with bipolar disorder. Key words: bipolar disorder,
comorbidity, health-related quality of life.
SF-12  Short Form 12 health-related quality of life assessment;
HRQOL  health-related quality of life; PCS  physical health
component score; MCS  mental health component score; CIVIC-
MD  Continuous Improvement for Veterans in Care: Mood Dis-
orders study; ISS  Internal State Scale; PTSD  posttraumatic
stress disorder; RMSEA  root mean square error of approximation;
TLI  Tucker-Lewis Index; CFI  comparative fit index.
INTRODUCTION
Bipolar disorder is one of the top ten most disabling conditionsand is associated with substantial functional impairment (1,2)
and healthcare costs (3,4). This illness is characterized by alter-
nating manic and depressive episodes and is estimated to affect
up to 5.5% of the U.S. population (5). When untreated, bipolar
disorder can increase the risk of co-occurring medical and sub-
stance use disorders (6,7), frequent hospitalizations (8), and ad-
verse outcomes including premature mortality (9).
Not surprisingly, health-related quality of life (HRQOL) in
patients with bipolar disorder (8) has been reported to be
lower than in the general population, even among those not
reporting current manic or depressive episodes (8,10), and
among those with bipolar disorder Type II (11). HRQOL is an
important indicator of current functioning and prognosis
(12,13), and low HRQOL is consistently associated with in-
creased risk of mortality across several chronic conditions
(14,15) including mental disorders (16).
Achieving symptom remission is considered one of the
essential treatment goals for persons with bipolar disorder.
However, there is a growing realization that these individuals
experience a substantial prevalence of co-occurring substance
use and medical disorders (7,17), which can also adversely
affect symptom remission and contribute to poor outcomes
including lower HRQOL. The few observational studies char-
acterizing physical and mental HRQOL in patients with bipo-
lar disorder have been cross-sectional in nature (2,8,18,19),
limited to selective randomized, controlled trials (20), or have
not controlled for co-occurring medical or substance use dis-
orders (21). Understanding the extent to which co-occurring
conditions contribute to worsening symptomatology and sub-
sequent HRQOL over time within a naturalistic treatment
setting is central to the process of tailoring treatment strategies
for patients with this illness (22).
The goal of this study is to assess changes in HRQOL over a
1-year period and to determine whether co-occurring conditions
were associated with lower HRQOL independent of bipolar
symptomatology, based on a naturalistic cohort of patients with
bipolar disorder. We hypothesized that co-occurring substance
use and medical conditions will be associated with decreased
physical and mental HRQOL scores in 12 months, after control-
ling for other patient factors, and this effect will be mediated by
increased manic and depressive symptoms.
METHODS
This is a prospective, longitudinal cohort study based on the Continuous
Improvement for Veterans in Care: Mood Disorders (CIVIC-MD) study,
designed to identify the predictors of poor outcomes among individuals with
bipolar disorder. Patients from a large Veterans Affairs (VA) medical center
in the mid-Atlantic region, who were diagnosed and treated for bipolar
disorder based on medical record review and confirmation of diagnosis from
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the patient’s mental health clinician between July 2004 and July 2006, were
consented, enrolled, and asked to complete a baseline and 1-year follow-up
survey that included measures of demographic characteristics, substance use
history, manic and depressive symptoms, treatment preferences, and HRQOL.
Additional data on co-occurring medical conditions were ascertained from
VA claims data. Patient inclusion criteria included current recorded diagnosis
of bipolar disorder (Type I or II) confirmed by their provider. Exclusion
criteria included unstable acute medical conditions, acute psychiatric symp-
toms (defined as current manic or psychotic episode at the time of enrollment
that precluded informed consent as determined by their mental healthcare
provider), or significant cognitive impairment that precluded informed con-
sent. Further details regarding CIVIC-MD are available elsewhere (23). This
study was reviewed and approved by local Institutional Review Boards, and
all subjects provided their informed consent.
Measures
Our primary outcome, HRQOL, was assessed using the Short Form
(SF-12) measure in the baseline and 1-year follow-up surveys (24). As with
the longer version of this HRQOL assessment (SF-36), the SF-12 is a
self-reported, 12-item assessment that ascertains the impact of physical and
mental symptoms on the ability to function in a series of daily tasks, vigor,
pain, and one’s self-perceptions of overall health compared with others. The
SF-12 generates two scores—the mental health component score (MCS) and
physical health component score (PCS). The MCS and PCS are highly
correlated with the longer SF-36 summary scores for MCS and PCS (r  0.92
and 0.91, respectively) (24).
Bipolar disorder symptoms were ascertained at baseline and follow-up,
using the Internal State Scale (ISS), a 15-item self-completed instrument that
assesses bipolar disorder symptom severity (25). Two symptom subscales
were created based on the ISS, representing symptoms of mania and depres-
sion, respectively. Each subscale is comprised of a set of symptoms, and the
patients self-reported the degree to which they experienced each symptom,
using a Likert scale (from 0  “not all all/rarely” to 100  “very much so”).
For the mania subscale, possible scores range from 0 to 50 points, with a
higher score indicating more severe manic symptoms. For the depression
subscale, scores range from 0 to 20 points, with higher scores indicating more
severe depressive symptoms. The ISS has a test-retest reliability exceeding
0.8 and prior research indicated that these subscales are highly correlated with
clinician ratings of mania and depression (25).
Co-occurring conditions were estimated, using measures for substance use
disorders, including alcohol (hazardous or binge drinking) and illicit drug use
ascertained from the patient baseline survey, and general medical conditions
ascertained from medical record data. Hazardous (binge) drinking was de-
fined as whether the patient reported having 5 drinks on one occasion at any
time within the past year (26). This assessment was strongly correlated with
clinician assessments of alcohol use disorders (sensitivity  0.95; specific-
ity  0.69). Any current illicit drug use (defined as marijuana, cocaine,
methamphetamines or other stimulants, heroin or other opioids, hallucino-
gens, ecstasy, and sedatives/hypnotics) was ascertained based on questions
regarding the past year, using Composite International Diagnostic Interview
Short Form (27). Compared with full-length Diagnostic Interview Survey
assessments for drug use disorders, the sensitivity of the Composite Interna-
tional Diagnostic Interview Short Form was 92% and the specificity was 91%.
Co-occurring medical conditions were ascertained from the VA electronic
medical record data. Medical diagnosis data were ascertained on or within 1
year before the enrollment date based on International Classification of
Diseases-9th Revision (ICD-9 CM) diagnostic codes, categorized by organ
system using a previously established method (19). We also assessed for the
presence of current anxiety symptoms (yes/no) based on a screener question
from the Patient Health Questionnaire (28) and posttraumatic stress disorder
(PTSD), based on VA electronic medical record data.
Other patient sociodemographic information (age, race, sex, marital sta-
tus, living alone or not, and college education or less than a college education)
were assessed, using the baseline survey questions. Bipolar subtype (Type I or
Type II) from provider confirmation was also ascertained.
Analyses
Two analytic approaches were used to test our hypothesis that the asso-
ciation between co-occurring conditions and decreased physical and mental
HRQOL is explained (mediated) by increased manic and depressive symp-
toms over the 12-month period. First, we employed multivariate linear re-
gression to assess the longitudinal predictors of changes in HRQOL physical
and mental health scores over the 1-year period. Second, we used path
analysis to detail to what extent bipolar symptoms explained decreases in
physical and mental health HRQOL independent of co-occurring conditions.
Multivariate Linear Regression
Change scores were created for the SF-12 physical (PCS) and mental
health (MCS) composite scores as well as for the depressive and manic
symptom scales based on the baseline and 1-year follow-up surveys. Two
linear regression models for each outcome (MCS and PCS) were run to
determine the independent effect of co-occurring substance use and medical
disorders on SF-12 change scores, and whether manic and depressive symp-
tom change scores explained these changes. The first model controlled for
patient demographics (age, race, gender, live alone, married, college edu-
cated), SF-12 baseline score, and co-occurring conditions at baseline (binge
drinking, illicit drug use, number of medical comorbidities diagnosis of
PTSD, diagnosis of bipolar disorder Type II (versus Type I), and presence of
anxiety symptoms and PTSD diagnosis). The second (full) model added the
effect of manic and depressive symptom scores at baseline and symptom
change scores. Adjusted R2 values were used to assess regression model fit.
Path Analysis
Path models were used confirm our hypotheses by testing the direct and
indirect pathways linking comorbidities and manic/depressive symptoms to
HRQOL. An advantage of path analysis is the capability examining depres-
sion and mania within a set of temporally ordered and feedback relationships,
which is not possible with multivariate linear regression. To achieve a
parsimonious model, the primary independent variables (depression and ma-
nia), primary outcome variables (i.e., mental and physical HRQOL), and a
subset of control variables that were statistically significant in the regression
analyses were included. Path models were tested, using Mplus software
(version 4.2) with maximum likelihood estimation. Model fit was based on
the 2 test and goodness-of-fit statistics, the root mean square error of
approximation (RMSEA), Tucker-Lewis Index (TLI), and comparative fit
index (CFI).
RESULTS
Overall, 720 patients were screened at the facility; of those,
616 patients were deemed eligible for participation. Of the 616
patients, 468 (76%) were enrolled between July 2004 and July
2006. The remaining patients were not enrolled due to a lack
of time for them to complete the survey (e.g., due to a pending
outpatient appointment). Of the 468 patients, 435 (92%) com-
pleted the baseline survey and 334 (77%) completed the
follow-up survey. Those who completed both the baseline and
follow-up surveys were similar in demographic and clinical
characteristics to those who did not complete the follow-up
survey, with a few exceptions. The mean age for both groups
was 49 years and 16% of those completing both the baseline
and follow-up surveys were women versus 10% not complet-
ing the follow-up survey. In addition, comparing completers
and noncompleters, the mean number of comorbidities was
2.6 and 2.9, respectively.
Baseline manic and depressive symptom scores were also
similar between the two groups: for mania, the scores were
19.9 and 18.2, respectively; for depression, scores were 7.9
and 7.2, respectively. HRQOL scores at baseline were also
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similar, with PCS scores 37.9 and 37.6, respectively, and MCS
scores 31.7 and 32.0, respectively. The prevalence of anxiety
symptoms was also similar between the two groups: 68%
versus 72%, respectively. Significant differences in patient
characteristics were only found for race/ethnicity: whites were
less likely to complete the follow-up survey (69% versus 79% in
the completer and noncompleter groups, respectively; p  .05).
Moreover, those completing the survey were less likely to have
an illicit drug use diagnosis (25% versus 37%; p  .05).
Table 1 reports demographic results for those completing
both baseline and follow-up surveys (n  334). The mean age
of the sample was 49 years (SD  10.6 years; range  21–78
years), 62 (14%) was female, and 61 (14%) were African
American. Twenty-six percent had a diagnosis of bipolar
disorder Type II, and the remaining sample had Type I. Over
a third reported living alone, and 17% graduated from college.
Twenty-one percent reported hazardous drinking, 28% re-
ported illicit drug use, and over two thirds reported anxiety
symptoms at baseline (Table 1). The mean number of co-
occurring medical conditions was 2.77 (SD  2.05) and mean
manic and depressive symptoms scores were 18.6 (SD 
13.0) and 7.8 (SD  6.2), respectively, at baseline. Baseline
mean SF-12 PCS and MCS scores were 38.0 (SD  7.6) and
32.0 (SD  7.7), respectively, and these values were similar in
the follow-up survey results (data not shown).
Multivariate Linear Regression
For SF-12 mental HRQOL, illicit drug use was associated
with decreased mental HRQOL (  1.41; p  .05). There
was no significant effect of medical comorbidities on mental
HRQOL in the first multivariable regression model (Table 2).
In the full regression model, increased depressive symptom
scores were strongly associated with decreased MCS scores 1
year later (  0.61; p  .001). Still, the effect of illicit drug
use was significant after adjusting for manic and depressive
symptoms (  2.01; p  .05). Adding manic and depres-
sive symptoms substantially improved model fit (adjusted R2
changes from .30 to .46), indicating that depressive symptoms
explained much of the variance in mental health change
scores. Other clinical factors including bipolar II diagnosis or
PTSD diagnosis were not associated with changes in mental
HRQOL.
TABLE 1. Baseline Characteristics of Patients With Bipolar
Disorder (n  334)
Patient Characteristics




African American 36 (10.8)
Other 33 (9.9)
Living alone 122 (36.5)
Married 108 (32.3)
Education
College graduate 61 (18.4)
Some college 158 (47.6)
Less than college 113 (34.0)
Bipolar disorder type II 85 (25.9)
Binge drinking 66 (19.8)
Any illicit drug use 85 (25.5)
Current anxiety symptoms 228 (68.3)
PTSD diagnosis 22 (6.9)
# Medical comorbidities 2.70  2.02
Bipolar symptoms (Internal State Scale)
Baseline manic symptom score
(range  0–50)
18.2  13.0
Baseline depressive symptom score
(range  0–20)
7.9  6.2
Health-related quality of life (SF-12)
Physical health composite score
(range  20–56)
38  7.6
Mental health composite score
(range  6–57)
32  7.6
Data are represented as means  SD or as n (%).
SD  standard deviation; PTSD  posttraumatic stress disorder; SF-12 
Short Form 12 health-related quality of life assessment.
TABLE 2. Bipolar Disorder Symptoms, Co-occurring Conditions,






Model I Model II Model I Model II
Adjusted R2 .30 .46 .32 .33
Intercept 21.60*** 30.49*** 27.12*** 28.51***
HRQOL baseline
scorea
0.65*** 0.80*** 0.56*** 0.57***
Age (continuous) 0.01 0.01 0.09* 0.09*
Female 0.80 1.13 2.31* 2.23*
African American 1.64 2.01 1.07 1.12
Other minority 1.82 0.27 2.21 1.98
Live alone 0.48 0.36 0.08 0.13
Married 0.22 0.14 0.64 0.66
College education
or greater
0.94 0.62 1.00 0.95
Bipolar II 0.78 1.01 1.14 1.14
Binge drinking 1.01 1.24 0.94 0.75
Any illicit drug use
disorder
1.41 2.01* 1.75* 1.72*
# Co-occurring
medical cond.
0.06 0.07 0.74** 0.71**
Anxiety symptoms 0.49 0.29 0.60** 0.26








Manic Sx-change 0.04 0.01
* p  .05; ** p  .01; *** p  .001.
a For the MCS outcome model, MCS baseline score was added; for the PCS
outcome model, baseline PCS score was added.
HRQOL  healthy-related quality of life; MCS  mental health component
score; PCS  physical health component score; Model I  patient demo-
graphics and comorbidities; Model II  added manic and depressive symp-
toms; cond.  condition; PTSD  posttraumatic stress syndrome; Sx 
symptoms.
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For the SF-12 PCS, increased number of co-occurring
medical conditions was associated with decreased PCS over
time (  0.74; p  .01). The presence of anxiety symp-
toms was also associated with decreased PCS (  0.60;
p  .01). After controlling for manic and depressive symp-
toms, PCS change scores were still significantly associated
with number of co-occurring medical conditions, but not for
anxiety symptoms (Table 2). Depressive symptoms may have
explained the association between anxiety and PCS decline
(Table 2). Older patients and women were also more likely to
experience decreased SF-12 PCS scores over time, and these
effects remained after controlling for manic and depressive
symptoms. Having a bipolar II diagnosis or PTSD diagnosis
was not associated with changes in physical HRQOL. Both the
first and full models demonstrated good overall fit (adjusted
R2  .32 and .33, respectively). A relatively high R2 (.30)
for both models indicates that medical comorbidities ex-
plained much of the effect on HRQOL changes over time
(Table 2).
Path Analysis Results
We first describe the path analysis setup and then the final
path analysis results. Two path models were fit to the data—
one model using MCS as the outcome and the other using
PCS. For the MCS model, the primary independent variables
(i.e., mania and depression) and other significant control vari-
ables based on the foregoing regression analyses (i.e., gender,
age, co-occurring substance use, and medical conditions) were
included. Binge drinking, although not statistically significant
in the regression models, was also included in the model due
to its high prevalence in the study sample and prior research
showing its effect on mental health and physical functioning.
Baseline variables had paths pointing directly to the MCS
baseline scores. The control variables also pointed to the
follow-up measures of mania and depression. However, these
paths were nonsignificant and subsequently trimmed to reduce
the complexity of the models and likelihood of overfitting the
data. Paths from the baseline measure of PCS and follow-up
measures of mania and depression pointed to the follow-up
measure of PCS. Finally, a reciprocal relationship between
mania and depression at follow-up was specified. The final
PCS model was constructed in the same manner, with the PCS
measures replacing all MCS measures.
The final path analysis models are depicted graphically in
Figure 1. The MCS model exhibited a good fit with the data,
based on a nonsignificant 2 value (2[20]  22.55, p  .31),
an RMSEA value that was 0.05 (RMSEA  0.02, 95%
Confidence Interval [CI]  0.00–0.06) and TLI and CFI
values that were 0.90 (TLI  0.99; CFI  0.99). As de-
picted in Figure 1A, baseline depression but not mania was
associated with lower. Lower baseline MCS were also asso-
ciated with being female, binge drinking, and drug use. Sim-
ilarly, depression but not mania at 1-year follow up was
associated with lower follow-up MCS. In the specified recip-
rocal relationship between depression and mania, depression
exhibited a significant effect on mania, but mania did not have
a significant effect on depression.
The physical health path model also exhibited a good fit
with the data. The 2 was statistically significant (2[19] 
27.51, p  .28). The RMSEA value was 0.02 (95% CI 
0.00–0.06), and the TLI and CFI were both 0.99. Lower
baseline PCS were significantly associated with higher base-
Figure 1. Path model representing health-related quality of life using baseline and 1-year follow-up data. a). Mental health-related quality of life; b). Physical
health-related quality of life. *p  .05; **p  .01; Medical Comorbidity  number of co-occurring medical conditions; Mania  manic symptom score;
Depression  depression symptom score.
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line depression scores and co-occurring medical conditions
but none of the other baseline measures. Follow-up PCS were
associated with follow-up depression and baseline co-occur-
ring medical conditions, but not mania at follow-up or any of
the other baseline measures (Fig. 1B). Again, similar to the
mental health model, depression exhibited a significant influ-
ence on mania, but mania did not have a significant effect on
depression.
DISCUSSION
The HRQOL in patients with bipolar disorder in this sam-
ple was significantly diminished, with scores that were on
average 12 to 18 points lower than the national norm of 50.
Moreover, longitudinal regression and path analyses indicate
that illicit drug use was associated with worse mental
HRQOL, and co-occurring medical conditions were associ-
ated with worse physical HRQOL, independent of manic/
depressive symptoms or other patient factors.
The association between co-occurring medical conditions
and physical HRQOL has been observed in prior cross-sec-
tional studies of patients with bipolar disorder (19). Our path
analyses confirmed an independent effect of baseline medical
conditions on both baseline and follow-up physical HRQOL
scores, independent of depressive symptoms, suggesting that
medical comorbidity has a substantial impact on the function-
ing and well-being of patients with bipolar disorder. Similarly,
the impact of illicit drug use on declining mental HRQOL
scores remained after controlling for bipolar symptoms. Still,
we were surprised to find that medical burden was not directly
associated with decreased mental HRQOL. This may reflect
increased coping or resilience among patients with chronic
medical conditions.
Although depression exhibited a strong and consistent in-
fluence on both mental and physical health scores over time,
it did not seem to mediate or explain away the effects of illicit
drug use on decreased mental HRQOL, or medical comorbidi-
ties on decreased physical HRQOL over time. Still, the ob-
served effects of co-occurring medical and substance use
disorders on HRQOL were very consistent across regression
and path analyses and highlight the importance of examining
the relationship between symptoms and HRQOL over time.
We also observed no significant effect of PTSD diagnosis
on changes in mental or physical HRQOL over time. More-
over, no significant difference was observed in HRQOL
scores by bipolar subtype (I, II). Previous studies, notably
Maina et al. found lower HRQOL scores in bipolar II com-
pared with bipolar I patients (11,17). In our study, bipolar
subtype was not confirmed via structured clinical assessment,
and hence, clinicians may have been unable to confirm bipolar
subtype distinguished subtype in routine clinical care. We also
found little effect of anxiety symptoms or PTSD diagnosis on
HRQOL after controlling for other comorbidities. Albert et al.
(29) found that, although the current prevalence of anxiety
disorders was similar between patients with bipolar I and II,
the negative association between anxiety disorder and
HRQOL subscale scores was primarily observed in those with
bipolar I disorder. Because we only screened for symptoms,
further longitudinal research on the impact of anxiety disorder
on functioning and outcome among patients with bipolar
disorder is warranted.
To our knowledge, this is the first longitudinal study of
HRQOL in bipolar disorder. Prior studies of HRQOL in
bipolar disorder have been cross- sectional in nature and did
not show whether mood states or symptoms lead to changes in
HRQOL over time (17,29). Advantages to our current study
included the availability to examine longitudinally the mediating
factors of poor HRQOL using path analysis, and consideration of
co-occurring medical and substance use disorders.
These results highlight the importance of considering the
impact of co-occurring conditions on HRQOL among patients
with bipolar disorder. Co-occurring substance use and general
medical conditions are increasingly recognized as important
contributors to lower functioning and poor outcomes in pa-
tients with bipolar disorder (7,16), and can substantially affect
survival in this group (30). Similarly, our results suggest that
addressing co-occurring substance use disorders in these pa-
tients (31) and co-occurring medical conditions (32) could
potentially improve overall functioning and quality of life for
these patients.
In addition, there is a consistent, detrimental, and long-term
impact of depression on HRQOL. Thus, treating depression in
those with bipolar disorder is essential as part of the process of
alleviating current symptomatology as well as improving
longer-term functioning. However, the treatment of depres-
sion is difficult and recent results indicated that adjunctive
antidepressant treatment may not significantly decrease de-
pressive symptoms in those with bipolar disorder (33). It is
interesting to note that several psychosocial interventions for
bipolar disorder utilize strategies that directly target aspects of
quality of life (e.g., family functioning, behavioral activation,
improving social support) as part of a focus on management of
depressive symptoms (22,31–34). The present results indicate
that this more comprehensive approach may be one way to
break the tie between depression and poorer functioning in
patients with bipolar disorder.
This study has a number of strengths including a relatively
large sample size, availability of longitudinal data on a stan-
dardized outcome measure for which population norms exist
(HRQOL), and a data analytic approach that incorporates both
regression and path analyses However, there are limitations to
this study that warrant consideration. First, CIVIC-MD was
limited to a single site; we were unable to enroll all eligible
patients. Second, to reduce respondent and provider burden
and reduce barriers to study entry, we relied on diagnoses
based on medical record and confirmed by clinicians rather
than formal structured psychiatric interview, as we did not
examine other comorbidities, such as obesity. We were also
unable to include assessment of the severity of anxiety symp-
toms. Although structured psychiatric interviews (e.g., Struc-
tured Clinical Interview for DSM-IV) can be lengthy and
potentially burdensome for patients, they are considered the
gold standard, and may preclude our ability to assess the effect
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of bipolar subtype (I, II) on HRQOL, and fully compare our
results from CIVIC-MD with results from other previously
published clinical cohorts that implemented formal diagnostic
assessment. In addition, we excluded from the study individuals
with acute medical conditions or acute psychiatric symptoms,
and our results might have been affected by the exclusion of
individuals with more severe or unstable conditions. Although
we wanted to include a more generalizable patient sample, there
are issues of consent for patients who are actively manic in a
study or otherwise lower functioning, for which there is no
potential direct benefit to the participant.
Moreover, it should be noted that the path analysis was
estimated, using maximum likelihood. An ideal estimator
would be weighted least squares given that the model included
dichotomous variables (i.e., gender, drug use, and binge drink-
ing) and count variables (i.e., number of co-occurring medical
conditions). This type of estimation was not possible, given
the requirements for very large sample sizes and less model
complexity. Although the estimates in models could be
slightly biased, it is important to note that the observed effects
were all in the expected directions and the effect sizes were in
a plausible range. The path models were included as supple-
mental test of the study hypotheses, complementing the
strengths and weaknesses of the linear regression models. In
addition, because we used the SF-12 to measure HRQOL as
opposed to the full-length SF-36, we were unable to assess
changes in SF-36 subscale scores (e.g., physical functioning,
energy) that have been used to compare HRQOL in other
bipolar disorder studies (11,29). Finally, the potential gener-
alizability of these findings may be limited to VA patients;
however, these individuals often represent the largely indigent
and comorbid patient populations seen in lower-income, com-
munity-based practice.
Overall, we found that, in a large sample of patients with
bipolar disorder, HRQOL scores were lower than the national
average. Moreover, substance use negatively affected mental
HRQOL over time, and co-occurring medical conditions were
associated with worse physical HRQOL over time in this
group. Changes in HRQOL over time can lead to increased
risk of mortality in persons with chronic conditions (13). Our
findings suggest the need for multipronged treatment strate-
gies for this group, notably interventions that address the
physical as well as drug treatment needs of patients with
bipolar disorder. Furthermore, applying both regression and
path analysis methods can confirm the identification of poten-
tial mediators of outcome, suggesting that this approach can
be used in future longitudinal studies in mental disorders.
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